The Journal of Urology
Volume 183, Issue 1 , Pages 234-240 , January 2010

Long-Term Durability of Percutaneous Tibial Nerve Stimulation for the Treatment of Overactive Bladder

  • Scott A. MacDiarmid

      Affiliations

    • Alliance Urology Specialists, Greensboro, North Carolina
    • Corresponding Author InformationCorrespondence: Alliance Urology Specialists, Bladder Control and Pelvic Pain Center, 509 N. Elam Ave., Second Floor, Greensboro, North Carolina 27403 (telephone: 336-274-1114; FAX: 336-232-5337)
    • Financial interest and/or other relationship with Uroplasty, Pfizer, Watson, Astellas and Allergan.
    • ,
  • Kenneth M. Peters

      Affiliations

    • William Beaumont Hospital, Royal Oak, Michigan
    • Financial interest and/or other relationship with Medtronic, Advanced Bionics, Boston Scientific, Allergan, Pfizer, Celgene and Trillium Therapeutics.
    • ,
  • S. Abbas Shobeiri

      Affiliations

    • University of Oklahoma, Oklahoma City, Oklahoma
    • ,
  • Leslie S. Wooldridge

      Affiliations

    • Mercy Health Partners, Muskegon, Michigan
    • Financial interest and/or other relationship with Uroplasty, Astellas and Watson.
    • ,
  • Eric S. Rovner

      Affiliations

    • Medical University of South Carolina, Charleston, South Carolina
    • Financial interest and/or other relationship with Uroplasty, Pfizer, Allergan, Tengion, Solace, Contura and Astellas.
    • ,
  • Fah Che Leong

      Affiliations

    • St. Louis University, St. Louis, Missouri
    • Financial interest and/or other relationship with Astellas.
    • ,
  • Steven W. Siegel

      Affiliations

    • Metro Urology, Woodbury, Minnesota
    • Financial interest and/or other relationship with AMS, Medtronic, Uromedica, Uroplasty and QiG.
    • ,
  • Susan B. Tate

      Affiliations

    • University of Louisville, Louisville, Kentucky
    • Financial interest and/or other relationship with C. R. Bard.
    • ,
  • Brian A. Feagins

      Affiliations

    • Dallas Center for Pelvic Medicine, Dallas, Texas
    • Financial interest and/or other relationship with Medtronic, AMS, Novartis, Allergan, Astellas and Boston Scientific.

Received 20 June 2009

References 

  1. ICS (International Continence Society) Factsheet 2–Overactive Bladder, 2005. http://www.icsoffice.org/ASPNET_Membership/Membership/Documents/DocumentsDownload.aspx?DocumentID=284Accessed May 2009
  2. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20:327
  3. Nitti VW. The prevalence of urinary incontinence. Rev Urol. 2001;3:S2
  4. Dmochowski RR, Newman DK. Impact of overactive bladder on women in the United States: results of a national survey. Curr Med Res Opin. 2007;23:65
  5. Pelletier EM, Vats V, Clemens Q. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder. Am J Manag Care. 2009;15:S108
  6. Starkmarn JS, Wolter CE, Scarpero HM, et al. Management of refractory urinary urge incontinence following urogynecological surgery with sacral neuromodulation. Neurourol Urodyn. 2007;26:29
  7. Zinkgraf K, Quinn AO, Ketterhagen D, et al. Percutaneous tibial nerve stimulation for treatment of overactive bladder and urinary retention in an elderly population. Urol Nurs. 2009;29:30
  8. Govier FE, Litwiller S, Nitti V, et al. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of multicenter study. J Urol. 2001;165:1193
  9. Klingler HC, Pycha A, Schmidbauer J, et al. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000;56:766
  10. Vandoninck V, van Balken MR, Finazzi-Agro E, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 2003;22:227
  11. van Balken MR, Vandoninck V, Gisolf K, et al. Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction. J Urol. 2001;166:914
  12. Peters KM, MacDiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy (OrBIT) Trial. J Urol. 2009;182:1055
  13. Peters KM, Killinger KA, Ibrahim IA, et al. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequency. Neurourol Urodyn. 2008;27:775
  14. Sand P and Zinner N: What is urgency? Examining the clinical adequacy of the ICS definition of urgency. Presented at the 2005 ICS Conference, Montreal, Canada, abstract 56.
  15. Coyne KS, Matza LS, Thompson CL. The responsiveness of the Overactive Bladder Questionnaire (OAB-q). Qual Life Res. 2005;14:849
  16. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11
  17. van der Pal F, Heesakkers JP, Bemelmans BL. Current opinion on the working mechanisms of neuromodulation in the treatment of lower urinary tract dysfunction. Curr Opin Urol. 2006;16:261
  18. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review. J Urol. 2006;175:835
  19. Flynn MK, Amundsen CL, Perevich MA, et al. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J Urol. 2009;191:2608
  20. Pfizer. Detrol® LA Instructions for Use. 2006;
  21. Nitti VW, Dmochowski R, Sand PK, et al. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007;178:2488
  22. Zinner N, Gittelman M, Harris R, et al. Trospium chloride improves overactive bladder symptoms: a multicenter phase III trial. J Urol. 2004;171:2311
  23. MacDiarmid SA, Staskin DR. Percutaneous tibial nerve stimulation (PTNS): a literature-based assessment. Curr Blad Dys Rep. 2009;4:29
  24. Kohli N, Rosenblatt PL. Neuromodulation techniques for the treatment of the overactive bladder. Clin Obstet Gynecol. 2002;45:218
  25. Amundsen CL, Romero AA, Jamison MG, et al. Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure?. Urology. 2005;66:746
  26. Wooldridge LS. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urinary urgency and urge incontinence: results from a community-based clinic. Urol Nurs. 2009;29:177
  27. Peters K, Carrico D, Burks F. Validation of a sham for percutaneous tibial nerve stimulation. Neurourol Urodyn. 2009;28:58

 Supported by Uroplasty, Inc.

 Study received institutional review board approval.

 See Editorial on page 17.

PII: S0022-5347(09)02381-7

doi: 10.1016/j.juro.2009.08.160

The Journal of Urology
Volume 183, Issue 1 , Pages 234-240 , January 2010

Article Tools

* Image Usage & Resolution